SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
210.1 EUR
+0.2 (+0.1%)
56S1 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- 56S1 had a positive operating cash flow in the past year.
- Each year in the past 5 years 56S1 has been profitable.
- 56S1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.36%, 56S1 is in line with its industry, outperforming 40.91% of the companies in the same industry.
- The Return On Equity of 56S1 (6.55%) is comparable to the rest of the industry.
- 56S1 has a Return On Invested Capital of 5.94%. This is comparable to the rest of the industry: 56S1 outperforms 54.55% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 9.34%.
- The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- The Profit Margin of 56S1 (8.98%) is comparable to the rest of the industry.
- In the last couple of years the Profit Margin of 56S1 has declined.
- 56S1 has a better Operating Margin (16.63%) than 63.64% of its industry peers.
- In the last couple of years the Operating Margin of 56S1 has declined.
- 56S1 has a Gross Margin (45.64%) which is in line with its industry peers.
- 56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- 56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, 56S1 has more shares outstanding
- The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
- The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
- 56S1 has an Altman-Z score of 4.50. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
- 56S1 has a better Altman-Z score (4.50) than 72.73% of its industry peers.
- 56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
- 56S1 has a Debt to FCF ratio (6.84) which is in line with its industry peers.
- 56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
- 56S1 has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.5 |
ROIC/WACC0.64
WACC9.34%
2.3 Liquidity
- 56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 63.64% of the companies in the same industry.
- 56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.50, 56S1 is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 35.11% over the past year.
- 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
- Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 7.72% in the last year.
- Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
- Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 9.86% on average per year.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 48.75, the valuation of 56S1 can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, 56S1 is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 39.13, the valuation of 56S1 can be described as expensive.
- 77.27% of the companies in the same industry are cheaper than 56S1, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.26. 56S1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.75 | ||
| Fwd PE | 39.13 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a rather expensive valuation: 56S1 more expensive than 81.82% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, 56S1 is valued a bit more expensive than the industry average as 63.64% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.59 | ||
| EV/EBITDA | 28.11 |
4.3 Compensation for Growth
- 56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as 56S1's earnings are expected to grow with 23.06% in the coming years.
PEG (NY)1.66
PEG (5Y)11.62
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
- 56S1 has a yearly dividend return of 0.32%, which is pretty low.
- 56S1's Dividend Yield is slightly below the industry average, which is at 0.53.
- Compared to an average S&P500 Dividend Yield of 1.87, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- 56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.37%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/15/2026, 7:00:00 PM)
210.1
+0.2 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-16 2025-10-16/bmo
Earnings (Next)02-03 2026-02-03/amc
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.45B
Revenue(TTM)2.95B
Net Income(TTM)264.50M
Analysts81.11
Price Target247.31 (17.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.37%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)2.75%
PT rev (3m)3.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.67%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.75 | ||
| Fwd PE | 39.13 | ||
| P/S | 6.94 | ||
| P/FCF | 54.59 | ||
| P/OCF | 27.99 | ||
| P/B | 5.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.11 |
EPS(TTM)4.31
EY2.05%
EPS(NY)5.37
Fwd EY2.56%
FCF(TTM)3.85
FCFY1.83%
OCF(TTM)7.51
OCFY3.57%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.66
PEG (5Y)11.62
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 112.98% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.75% | ||
| Profit Quality | 141.63% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.5 |
F-Score8
WACC9.34%
ROIC/WACC0.64
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
EBIT growth 1Y25.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.25%
FCF growth 1Y219.35%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.98%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 48.75 and the Price/Book (PB) ratio is 5.07.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.